Edoxaban shows Phase III benefits in knee surgery setting
This article was originally published in Scrip
Daiichi Sankyo has released further details of a Phase III study in which its novel oral anticoagulant edoxaban showed benefits over exoxaparin in the prevention of venous thromboembolic (VTE) events in patients undergoing total knee replacement surgery.
You may also be interested in...ï»¿
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.